Medicine and Dentistry
Adverse Event
12%
Allogeneic Stem Cell Transplantation
12%
Arm
12%
Autologous Stem Cell Transplantation
10%
Axicabtagene Ciloleucel
12%
B Cell
24%
B-Cell Chronic Lymphocytic Leukemia
10%
B-Cell Lymphoma
32%
Burkitt's Lymphoma
12%
Central Nervous System
14%
Chimeric Antigen Receptor T-Cell Immunotherapy
16%
Classical Hodgkin Lymphoma
17%
Cyclophosphamide
26%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Cytarabine
10%
Diffuse Large B-Cell Lymphoma
86%
Disease Exacerbation
11%
Diseases
72%
Doxorubicin
27%
Failure Free Survival
9%
Fludarabine
9%
Follicular Lymphoma
41%
Hazard Ratio
11%
Hodgkin's Lymphoma
29%
Ibrutinib
21%
International Prognostic Index
13%
Large-Cell Lymphoma
37%
Lenalidomide
17%
Lymphocytic Lymphoma
13%
Lymphoma Cell
12%
Malignant Neoplasm
28%
MALT Lymphoma
21%
Mantle Cell Lymphoma
44%
Methotrexate
13%
Neoplasm
12%
Non-Hodgkin Lymphoma
52%
Oncology
10%
Overall Survival
52%
Peripheral T-Cell Lymphoma
10%
Phase II Trials
12%
positron emission tomographic scan
15%
Positron Emission Tomography-Computed Tomography
16%
Prednisone
12%
Progression Free Survival
53%
Radiation Therapy
62%
Rituximab
73%
Survival Rate
26%
Systemic Therapy
9%
T Cell
11%
Vincristine
18%
Keyphrases
Advanced Stage
14%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
28%
B-cell Lymphoma
23%
B-cell non-Hodgkin Lymphoma (B-NHL)
14%
Bortezomib
15%
Chemotherapy
29%
Chimeric Antigen Receptor T-cell Therapy
18%
Complete Response
39%
Confidence Interval
13%
Cyclophosphamide
33%
Cytarabine
18%
Diffuse Large B-cell Lymphoma (DLBCL)
72%
Disease Progression
11%
Doxorubicin
25%
Failure-free Survival
13%
Fludarabine
13%
Follicular Lymphoma
45%
High Risk
15%
Hyper-CVAD
17%
Ibrutinib
16%
International Prognostic Index
12%
Large B-cell Lymphoma
27%
Lenalidomide
12%
Lymphoma
28%
Lymphoma Patients
23%
Mantle Cell Lymphoma
58%
Marginal Zone Lymphoma
12%
MD Anderson Cancer Center
14%
Methotrexate
13%
NCCN Guidelines
15%
Newly Diagnosed
19%
Non-Hodgkin Lymphoma
24%
Overall Response Rate
19%
Overall Survival
31%
Overall Survival Rate
11%
Partial Response
16%
Pentostatin
11%
Peripheral T-cell Lymphoma
12%
Phase II Study
30%
Phase II Trial
22%
Positron Emission Tomography-computed Tomography (PET-CT)
12%
Prednisone
14%
Previously Untreated
11%
Progression-free Survival
42%
R-CHOP
21%
Radiation Therapy
30%
Radiotherapy
14%
Relapsed or Refractory
54%
Rituximab
79%
T Cells
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Angiofollicular Lymph Node Hyperplasia
9%
Axicabtagene Ciloleucel
7%
B Cell Lymphoma
13%
Bortezomib
14%
Chemotherapy
44%
Chimeric Antigen Receptor
20%
Classical Hodgkin Lymphoma
9%
Clinical Trial
11%
Cyclophosphamide
38%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
18%
Cytarabine
21%
Danvatirsen
7%
Denileukin Diftitox
7%
Dexamethasone
18%
Diffuse Large B Cell Lymphoma
56%
Disease Exacerbation
9%
Diseases
44%
Doxorubicin
31%
Etoposide
9%
Event Free Survival
8%
Failure Free Survival
15%
Fludarabine
11%
Follicular Lymphoma
29%
Hodgkin Disease
14%
Ibrutinib
15%
Inotuzumab Ozogamicin
7%
Interleukin 6
7%
Large Cell Lymphoma
20%
Lenalidomide
17%
Malignant Neoplasm
28%
Mantle Cell Lymphoma
49%
Methotrexate
21%
Monoclonal Antibody
7%
Myelodysplastic Syndrome
6%
Neoplasm
11%
Neutropenia
10%
Nonhodgkin Lymphoma
50%
Obinutuzumab
9%
Overall Survival
35%
Pentostatin
7%
Phase II Trials
14%
Prednisone
16%
Progression Free Survival
38%
Remission
24%
Rituximab
100%
Siltuximab
7%
Survival Rate
22%
Thrombocytopenia
10%
Vincristine
28%